CoChat

Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?

Amaia Rodriguez, Victoria Catalan, Javier Gomez-Ambrosi, Gema Fruhbeck · 2007 · Current Pharmaceutical Design

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Abstract

The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upper-body obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed "adipokines"). Weight reduction and increased physical activity represent the main approach to tackle the "diabesity" epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.

Overview

Integrity signals

Registry

Crossref · 10.2174/138161207781039599

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 86 references

Cited by

See all 155

Metadata

Authors
Rodriguez, A., Catalan, V., Gomez-Ambrosi, J., & Fruhbeck, G.
Affiliations
Dept. of Endocrinology,Clinica Universitaria de Navarra, Avda. Pio XII 36, 31008-Pamplona,SPAIN.
Venue
Current Pharmaceutical Design
Published
2007-07-01
Volume
13
Issue
21
Pages
2169-2175
ISSN
1381-6128 (ISSN-L)
OpenAlex
W1994677499
Cited by
133
References
86
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 7 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 7 · 2014: 14 · 2013: 8 · 2012: 18
FWCI
6.19
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Gobierno de Navarra
  • Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
metabolic syndrome, visceral fat, subcutaneous adiposity, abdominal obesity, insulin resistance, adipokines, adipose tissue, obesity, cardiovascular risk, therapeutic target, diabesity
MeSH terms
Animals, Humans, Insulin, Lipolysis, Retinol-Binding Proteins, Tumor Necrosis Factor-alpha, Cytokines, Leptin, Metabolic Syndrome, Subcutaneous Fat, Intra-Abdominal Fat, Adiposity, Adiponectin, Nicotinamide Phosphoribosyltransferase, Retinol-Binding Proteins, Plasma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome? https://app.cochat.ai/papers/10.2174/138161207781039599
The paper
Rodriguez, A., Catalan, V., Gomez-Ambrosi, J., & Fruhbeck, G. (2007). Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome? Current Pharmaceutical Design. https://doi.org/10.2174/138161207781039599

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.